Effects of Roflumilast in Hospitalized COPD on Mortality and Re-hospitalization
Phase of Trial: Phase III
Latest Information Update: 23 May 2018
Price : $35 *
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 23 May 2018 Results (n=64) presented at the 114th International Conference of the American Thoracic Society.
- 19 Mar 2018 Status changed from active, no longer recruiting to completed.